Spread | 0.41 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 25.05 |
Open | 25.55 |
1-Year Change | 41.94% |
Day's Range | 25.54 - 26.12 |
XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The Company's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.
BRIEF: For the fiscal year ended 31 December 2021, XOMA Corp revenues increased 30% to $38.2M. Net income applicable to common stockholders decreased 12% to $8M. Revenues reflect Europe segment increase of 40% to $35M, United States segment increase from $1.3M to $2.6M. Net income was offset by Stock-based Compensation in SGA increase of 56% to $6.2M (expense).
Common Stock $.0075 Par, 03/11, 46,666,666 auth., 29,510,963 issd. Insiders own 7.83%. PO: 4/91, 3.4M shs @ $26.50 by Alex. Brown& Sons. PO 6/01, 3M shs @ $15 by U.S. Bancorp Piper Jaffray. Series B Prfd. Stock $.05 Par, 8K auth., 2,959 issd. *1996, Co.'s 4% Conv. Subd. Debentures were conv. into 2M shs. of Common. 08/10, 1-for-15 reverse split.